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Abstract
1,2-Diarylethylamines including lanicemine, lefetamine, and remacemide have clinical rele-
vance in a range of therapeutic areas including pain management, epilepsy, neurodegener-
ative disease and depression. More recently 1,2-diarylethylamines have been sold as ‘legal
highs’ in a number of different forms including powders and tablets. These compounds are
sold to circumvent governmental legislation regulating psychoactive drugs. Examples
include the opioid MT-45 and the dissociative agents diphenidine (DPH) and 2-methoxy-
diphenidine (2-MXP). A number of fatal and non-fatal overdoses have been linked to abuse
of these compounds. As with many ‘legal highs’, little is known about their pharmacology.
To obtain a better understanding, the effects of DPH, 2-MXP and its 3- and 4-MeO- isomers,
and 2-Cl-diphenidine (2-Cl-DPH) were investigated using binding studies at 46 central ner-
vous system receptors including the N-methyl-D-aspartate receptor (NMDAR), serotonin,
dopamine, norepinephrine, histamine, and sigma receptors as well as the reuptake trans-
porters for serotonin, dopamine and norepinephrine. Reuptake inhibition potencies were
measured at serotonin, norepinephrine and dopamine transporters. NMDAR antagonism
was established in vitro using NMDAR-induced field excitatory postsynaptic potential
(fEPSP) experiments. Finally, DPH and 2-MXP were investigated using tests of pre-pulse
inhibition of startle (PPI) in rats to determine whether they reduce sensorimotor gating, an
effect observed with known dissociative drugs such as phencyclidine (PCP) and ketamine.
The results suggest that these 1,2-diarylethylamines are relatively selective NMDAR antag-
onists with weak off-target inhibitory effects on dopamine and norepinephrine reuptake.
DPH and 2-MXP significantly inhibited PPI. DPH showed greater potency than 2-MXP,
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acting with a median effective dose (ED50) of 9.5 mg/kg, which is less potent than values
reported for other commonly abused dissociative drugs such as PCP and ketamine.
Introduction
1,2-Diarylethylamines represent a structural class of organic molecules, which all share a core
structure comprised of an ethylamine nucleus with vicinal aromatic substitutions. These com-
pounds have diverse pharmacology and modifications of this structure have yielded analgesics,
antidepressants, anticonvulsants and neuroprotective agents [1–3]. Their pharmacology
appears to be mediated through a range of interactions including activation of opioid receptors
[2, 4, 5], inhibition of monoamine transporters [6, 7] and antagonism of glutamatergic N-
methyl-D-aspartate receptors (NMDARs) [1, 8]. Clinical interest in 1,2-diarylethylamines
includes the well-tolerated NMDAR antagonist lanicemine, which exhibits antidepressant
activity[1], and remacemide, which has shown promise in clinical trials for several therapeutic
areas including neurodegenerative diseases, epilepsy and stroke [3]. Structures of some of these
are given as supporting information (S1 Fig).
Most recently, a variety of 1,2-diarylethylamines have appeared as ‘legal highs’ or ‘research
chemicals’ from online vendors. These include the opioid MT-45 [9, 10] and several dissocia-
tive agents such as diphenidine (DPH) and 2-methoxydiphenidine (methoxphenidine or
2-MXP) [11–13]. The dissociative diarylethylamines emerged as ‘legal highs’ or ‘research
chemicals’, to circumvent regulations on human consumption, shortly following a United
Kingdom ban (February 2013) on arylcyclohexylamine-based dissociative drugs such as meth-
oxetamine (MXE) and 3-methoxyphencyclidine (3-MeO-PCP) [13, 14]. Though DPH and
2-MXP were new to this market and had no previously documented history of human use, syn-
theses had been published as early as 1924 and 1989 respectively and both had undergone in
vitro screening for NMDAR affinity.[13] Images of products sold online are provided as sup-
porting information (S11–S13 Figs).
The phenomenology of the altered state induced by dissociative drugs is complex and dose
dependent. However, key features of the dissociative state include sensory hallucinations, tac-
tile distortions, euphoria, derealization and depersonalization [13]. A significant portion of the
therapeutic and psychoactive effects of dissociative drugs is believed to be mediated through
NMDAR antagonism [13, 15, 16]. Although NMDAR antagonism appears to be a common
denominator involved in the dissociative pharmacology, additional receptors are likely to con-
tribute to the effects of individual compounds [16].
Aside from some NMDAR binding studies [17, 18] and a recent publication about the
metabolism of DPH [19], little information has been published regarding the pharmacology of
the dissociative ‘research chemicals’ DPH and 2-MXP. Due to the increasing appearance of
1,2-diarylethylamine based ‘research chemicals’ [11–13] along with reports of overdoses [20]
and fatal intoxications [21] it is important to investigate the pharmacology of these
compounds.
To extend earlier reports of NMDAR binding, competitive binding experiments with [3H]-
MK-801 were performed with DPH and 2-MXP, along with the methoxy- substituted posi-
tional isomers 3-methoxy-diphenidine (3-MXP) and 4-methoxy-diphenidine (4-MXP) as well
as 2-Cl-diphenidine (2-Cl-DPH) (Fig 1). The NMDAR antagonists, PCP, ketamine, (+)-MK-
801 and memantine served as reference compounds. NMDAR selectivity was investigated
using binding studies at an additional 45 CNS receptor sites including G protein-coupled
receptors (serotonin, dopamine, norepinephrine, histamine, acetylcholine subtypes),
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monoamine reuptake transporters for dopamine (DAT), norepinephrine (NET) and serotonin
(SERT), mu (MOR), kappa (KOR) and delta (DOR) opioid receptors and sigma-1 and sigma-2
receptor sites. Compounds were also evaluated for inhibition of monoamine reuptake to estab-
lish the functional consequences of the observed interactions with monoamine reuptake trans-
porters. To measure functional activity at central synapses in vitro, the target compounds along
with reference compounds were assessed on NMDA receptor-mediated field excitatory post-
synaptic potentials (NMDAR-fEPSP). Finally, in vivo pre-pulse inhibition (PPI) experiments
were performed with DPH and 2-MXP.
Materials and Methods
Target Compounds
Phencyclidine (PCP), memantine hydrochloride and (+)-MK-801 maleate were obtained from
Sigma-Aldrich.
Synthesis and analytical characterizations of the target 1,2-diarylethylamines have been
published elsewhere [11, 12]. The exception is 2-Cl-DPH, which was not described previously.
Details of the synthesis and analytical characterization of 2-Cl-DPH are provided as supporting
information (S6 File).
Fig 1. Structures of PCP and related arylcyclohexylamines, ‘legal highs’ DPH, 2-MXP and aryl-substituted
1,2-diarylethylamines.
doi:10.1371/journal.pone.0157021.g001
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NMDA Receptor Binding Studies
In vitro binding affinities (Ki) of the target compounds at the PCP site within the NMDAR
channel were determined using competitive radioligand binding studies with [3H]-MK-801 in
accordance with established protocols published by Reynolds and Sharma [22, 23]. Thoroughly
washed rat forebrain homogenate were used as the NMDAR source (whole brain obtained
from Pel-Freez Biologicals) and prepared as described by Reynolds and Sharma [22]. Suspen-
sions of 10 mMHEPES buffer (pH 7.4 at room temperature) containing 100 μg/mL protein, 1
nM (+)-[3H]-MK-801, 100 μM glutamate, 10 μM glycine, and various concentrations of unla-
beled competitor or 30 μM (+)-MK-801 for nonspecific binding (and positive control), were
incubated in the dark on a mechanical rocker at room temperature for 2 h. The reaction was
terminated by vacuum filtration using a 24 well cell harvester (Brandel, Gaithersburg, MD)
over presoaked GF/B glass fiber filters (Brandel, Gaithersburg, MD). Filters were washed with
room temperature assay buffer (3 x 5 mL). Tritium trapped on the filter was measured via liq-
uid scintillation counting, using a Beckman LS 6500 multipurpose scintillation counter (Beck-
manCoulter, USA) at 57% efficiency. IC50 values were determined in Graphpad Prism 5.0
using non-linear regression with log-concentration plotted against percent specific binding.
Percent specific binding for [3H]-MK-801 in a control experiment was ~95%. Ki values were
calculated using the equation of Cheng and Prusoff [24]. The Kd for (+)-MK-801 (1.747 nM),
was determined via homologous binding assay as described by Reynolds and Sharma and is
consistent with the literature [22]. Protein concentration was determined via the Bradford
method using Coomassie protein assay reagent (Sigma, USA) [25] with rat albumin (Sigma,
USA) as standard. Experiments were performed in duplicate and repeated a minimum of three
times. Raw counts per minute (CPM) for all NMDAR binding experiments are provided as
supporting information (S1 File).
Non-NMDA Receptor Binding Studies
Radioligands and concentrations used for additional 45 CNS receptor binding assays are listed
as supporting information (S1 Table). This work was performed by the National Institute of
Mental Health Psychoactive Drug Screening Program (NIMH PDSP) as described previously.
[26] Briefly target compounds were dissolved in DMSO and subjected to a primary screen at
10,000 nM concentration. Compounds exhibiting>50% inhibition were subjected to a second-
ary assay at varying concentrations to determine Ki values. Additional experimental details are
available in the NIMH PDSP assay protocol book [27].
Monoamine Reuptake Inhibition Assays
Monoamine reuptake inhibition assays were performed via the NIMH PDSP as previously
described.[28] In brief, the neurotransmitter transporter uptake assay kit (R8174) (Molecular
Devices) was used. Human monoamine transporters (DAT, NET and SERT) were stably
expressed in HEK293 cells. Assay buffer consisted of 20 mMHEPES, 1x HBSS at pH 7.4. Cells
were plated in Pol-L-Lys (PLL) coated 384-well black clear bottom cell culture plates with a
density of 15,000 cells/well. Cells were incubated for at least 6 h prior to assay. Media was
removed and replaced with 20 μL assay buffer and 5 μL of drug or positive control (cocaine or
nisoxetine) as a 5X stock. Cells were incubated for 30 min at 37°C. 25 μL of dye solution was
then added and following an additional 30 min incubation (at 37°C) fluorescence intensity was
measured using a FlexStation II (bottom read mode, excitation wavelength = 440 nM, emis-
sion = 520 nM with a cutoff of 510 nM). Relative florescence units were exported and plotted
against drug concentration to obtain 50% inhibition potencies (IC50) using non-linear regres-
sion (Prism 5.0). Additional details are available in the NIMH PDSP assay protocol book [27].
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In Vitro Field Excitatory Postsynaptic Potential (fEPSP) Experiments
Male Wistar rats (Crl:Wi; Charles River, UK) aged 9–10 wk were sacrificed by neck vertebral
dislocation (schedule 1 method) according to the United Kingdom (Scientific Procedures) Act
of 1986. After their rapid removal, brains were placed in artificial cerebrospinal fluid (aCSF)
consisting of 124 mMNaCl, 26 mMNaHCO3, 3 mM KCl, 1.4 mM NaH2PO4, 1 mMMgSO4, 2
mM CaCl2, and 10 mM D-glucose and continuously oxygenated with 95% O2 and 5% CO2.
The brain was cut parasagittally into 400 μm sections and hippocampal slices were removed,
stored and placed in a submerged recording chamber at 28–30°C. Recordings of synaptic activ-
ity were made, analyzed and presented as described [29, 30]. A bipolar electrode was used to
deliver stimuli (0.03 Hz) to the Schaffer collateral pathway to enable recording of field excit-
atory synaptic potentials (fEPSPs) using a glass microelectrode positioned in the stratum radia-
tum of area CA1. The NMDA receptor-mediated component of the fEPSP (NMDAR-fEPSP)
was revealed by adding 10 μMNBQX, 50 μM picrotoxin and 1 μMCGP 55845 to the aCSF,
which abolished AMPA and GABA receptor mediated transmission. After 30 min of stable
control responses, 1 and 10 μM solutions of the individual compounds were added to the per-
fusate for 3–12 h while recording the amplitude and area of the NMDAR-fEPSP on-line using
WinLTP [31]. Single exponential curves were fitted to the graphs and curves extrapolated to
show likely half-times and minimum plateau responses achieved with each concentration of
the compounds. Raw data for all fEPSP experiments are provided as supporting information
(S2, S3 and S4 Files).
In Vivo Pre-pulse Inhibition (PPI) Experiments
Animals
Male Sprague–Dawley rats from Harlan Industries (Indianapolis, IN, USA; initial weight 250–
275 g) were housed in pairs under a 12-h reverse light/dark cycle (lights off at 0700 h). Use of a
reversed light/dark cycle allows behavioral testing to be conducted during the awake phase of
the light/dark cycle. Food and water were available ad libitum. Animals were acclimatized for
approximately 1 wk after arrival prior to behavioral testing and maintained in Association for
Assessment and Accreditation of Laboratory Animal Care (AAALAC)-approved facilities that
meet all federal and state guidelines. Procedures were approved by the University of California
San Diego institutional animal care and use committee. Principles of laboratory animal care
were followed.
Drugs
DPH hydrochloride and 2-MXP hydrochloride were dissolved in water containing 5% Tween-
80 and administered subcutaneously, 10-min prior to the start of the startle test session. The
injection volume was 1 ml/kg.
Acoustic startle apparatus and test sessions
Apparatus. Eight startle chambers (SR-LAB system, San Diego Instruments, San Diego,
CA, USA) were used to measure startle reactivity in rats [32, 33]. The startle test chambers
were sound-attenuated, lighted, and ventilated enclosures containing a clear nonrestrictive
cylindrical Plexiglas stabilimeter, 8.2 cm in diameter. A high-frequency loudspeaker mounted
24 cm above the Plexiglas cylinder produced all acoustic stimuli. The peak and average ampli-
tudes of the startle response were detected by a piezoelectric accelerometer. At the onset of the
startling stimulus, 100 1-ms readings were recorded, and the average amplitude was used to
determine the magnitude of the startle response (measured in arbitrary units). A dynamic
Pharmacology of Dissociative Legal High 1,2-Diarylethylamines
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calibration system was employed to ensure comparable stabilimeter sensitivity across test
chambers, and sound levels were measured using the dB(A) scale.
Test sessions. Acoustic startle test sessions consisted of startle trials (pulse-alone) and pre-
pulse trials (prepulse + pulse). The pulse-alone trial consisted of a 40-ms 120-dB pulse of
broadband white noise. Prepulse + pulse trials consisted of a 20-ms acoustic prepulse, an
80-ms delay, and then a 40-ms 120-dB startle pulse (100-ms onset–onset). There was an aver-
age of 15 s (range = 6–22 s) between trials. During each inter-trial interval, the movements of
the animals were recorded once to measure response when no stimulus was present (data not
shown). Each startle session began with a 5 min acclimation period to a 65-dB broadband
noise that was present continuously throughout the session. One week after arrival, animals
were tested in a brief baseline startle/PPI session to create treatment groups matched for levels
of startle and PPI. The startle test session contained 12 pulse-alone trials and 36 prepulse
+ pulse trials (12 prepulses each of 68-, 71-, and 77-dB [equivalent to 3-, 6-, and 12-dB above
background]) presented in a pseudo-randomized order. Six pulse-alone trials were presented at
the beginning and the end of the test session but were not used in the calculation of PPI values.
Raw data for all PPI experiments are provided as supporting information (S5 File).
Analysis. The amount of PPI was calculated as a percentage score for each prepulse
+ pulse trial type: %PPI = 100−{[(startle response for prepulse + pulse trial)/(startle response
for pulse-alone trial)] × 100}. Startle magnitude was calculated as the average response to all of
the pulse-alone trials. PPI data were analyzed with two-factor analysis of variance (ANOVA)
with treatment as the between-subjects factor and trial type (prepulse intensity) as a repeated
measure. For experiments in which there was no significant interaction between drug and pre-
pulse intensity, PPI data were collapsed across prepulse intensity and average PPI was used as
the main dependent measure. ED50 values were calculated using nonlinear regression. Startle
magnitude data were analyzed with one-factor ANOVA. Post-hoc analyses were performed
using Tukey’s studentized range method. The alpha level was set at 0.05.
Results and Discussion
Receptor Binding affinities
NMDAR binding affinities for the test compounds are presented in Table 1. [3H]-MK-801 dis-
placement curves for the five 1,2-diphenylethylamines and reference compounds are provided
as supporting information (S3 and S4 Figs respectively). Four of the five compounds had
Table 1. NMDAR binding affinities for five target 1,2-diphenylethylamines and reference compounds
Compound IC50 ± SEM (nM) Ki ± SEM (nM)
PCP [34] 91 ± 1.3 57.9 ± 0.8
Ketamine 508.5 ± 30.1 323.9 ± 19.2
Memantine 594.2 ± 41.3 378.4 ± 26.3
(+)-MK-801 4.1 ± 1.6 2.5 ± 1.0
DPH 28.6 ± 3.5 18.2 ± 2.2
2-MXP 56.5 ± 5.8 36.0 ± 3.7
3-MXP 30.3 ± 2.6 19.3 ± 1.7
4-MXP 723.8 ± 69.9 461.0 ± 44.5
2-Cl-DPH 14.6 ± 2.1 9.3 ± 1.3
NMDAR binding afﬁnities determined using [3H]-(+)-MK-801 in rat forebrain. Mean ± SEM are presented
from four separate experiments run in duplicate.
doi:10.1371/journal.pone.0157021.t001
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potent nM affinity for [3H]-MK-801 labeled NMDARs. 4-MXP had lower NMDAR affinity
(461 nM) compared to the other members of the series. The rank order of potency of
DPH and its three MeO- isomers (DPH = 3-MXP> 2-MXP> 4-MXP) is comparable
with that seen with the equivalently substituted arylcyclohexylamines; with PCP = 3-MeO-
PCP> 2-MeO-PCP> 4-MeO-PCP [34]. The parallel structure activity relationships (SAR)
between aryl-methoxy substituted derivatives of PCP and DPH is not surprising given the
structural overlap between the benzyl-piperidine portions of PCP and DPH (Fig 1). Therefore,
the overlapping portions of arylcyclohexylamines and 1,2-diphenethylamines likely bind to the
same region of the PCP binding site within the NMDAR channel. SAR studies on arylcyclohex-
ylamines may have relevance for further optimization of 1,2-diarylethylamine-based NMDAR
antagonists.
Binding affinities for the test compounds at NMDAR were described previously in a patent
by Gray and Cheng [17]. Notably, in most cases the NMDAR binding affinities reported herein
differed from those earlier studies. The rank order of potencies were, however, consistent. Sur-
prisingly, Gray and Cheng reported 2-Cl-DPH to have pM affinity, an order of magnitude
higher than other known NMDAR antagonists. This report of high affinity binding reported
for 2-Cl-DPH prompted us to reinvestigate this compound in the present study. While in the
current study 2-Cl-DPH had potent low nM affinity for NMDAR (9.3 nM), this is substantially
less than the pM affinity reported previously. In a study by Berger et al., the two DPH enantio-
mers showed lower affinity than that reported both here and by Gray and Cheng ((S-)-DPH
120 nM, (R)-DPH 5,250 nM) [18]. Likewise, the reported affinity of PCP was ~4-fold lower
than that observed here and reported by others [35]. These discrepancies may result from the
fact that [3H]-TCP was used by Gray and Cheng while the more selective [3H]-MK-801 [36–
39] was used in the current study. Berger et al. used [3H]-MK-801 to label NMDAR from a dif-
ferent tissue source (whole cell membranes prepared from rat cortex and hippocampus) than
the current study (rat forebrain homogenate) [18]. Differences in affinities of the compounds
for different NMDAR subunit combinations might be one possible explanation.
Non-NMDA Receptor Binding Affinities
All the target compounds displayed lower affinities at all other CNS sites evaluated relative to
NMDAR with the exception of 4-MXP, the weakest NMDAR ligand, which had a ~2.5-fold
higher affinity at DAT than NMDAR. A heat map of binding results is presented in Fig 2,
which also shows experimentally determined Ki values for those receptors as well as for
NMDAR.
Most of the target compounds had weak affinity for the KOR whereas only 2-Cl-DPH
showed weak affinity (2,060 nM) for MOR. These results are consistent with the fact that sev-
eral related 1,2-diarylethylamines including lefetamine, AD-1211 and MT-45 (S1 Fig) act as
opioid agonists and analgesics [2, 4, 5, 40]. However the lack of high affinity suggests that the
1,2-diarylethylamines evaluated here do not act as opioids. Interactions with muscarinic recep-
tor subtypes (M1, M2, and M5) were generally weak. 2-Cl-DPH had the highest affinities of the
series for muscarinic sites, although affinities at these sites were 30-fold less than for NMDAR.
Most of the target compounds had submicromolar affinity for DAT, with 3-MXP exhibiting
the highest affinity (81 nM) followed by 4-MXP (157 nM), DPH (317 nM), 2-Cl-DPH (357
nM) and finally 2-MXP which had the weakest affinity (2,915 nM). Several target compounds
also had low affinity for NET, while notably none of the target compounds showed affinity for
SERT. The absence of SERT affinity was surprising in light of reports indicating that 1,2-diphe-
nylethylpiperazines act as norepinephrine/serotonin reuptake inhibitors with low DAT affinity
[6, 7]. Notably, in addition to having a piperazine ring in place of piperidine, most of the
Pharmacology of Dissociative Legal High 1,2-Diarylethylamines
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1,2-diphenylpiperzines investigated [6, 7] were substituted on the 2-phenyl ring as opposed to
the current compounds, which were substituted on the 1-phenyl ring. How substitutions on
the 2-phenyl ring influence NMDAR affinity or the psychoactive effects of
Fig 2. Heat map of receptor binding affinities observed for NMDAR and 45 additional receptor sites. Ki
values given in nM. Full green without numbers represents >10,000 nM in the primary screen.
doi:10.1371/journal.pone.0157021.g002
Pharmacology of Dissociative Legal High 1,2-Diarylethylamines
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1,2-diarylethylamines warrants investigation. A number of arylcyclohexylamines, including
MeO-PCP isomers, have affinity at monoamine reuptake transporters [34, 35]
Finally, moderate affinities were seen for the sigma-1 and sigma-2 receptors. Many arylcy-
clohexylamines, as well as other NMDAR antagonists, have high affinity for sigma receptors
[34]. The significance of these sigma receptor interactions on the effects of NMDAR antago-
nists is still unknown, although sigma receptors have been implicated in the regulation of a
large number of diverse neurotransmitter and physiological systems including dopaminergic
and glutamatergic neurotransmission (particularly sigma-1) [41–43], intracellular calcium
(sigma-1 and sigma-2) [43, 44] and may play roles in abuse liability and tolerance [43].
Monoamine reuptake inhibition. The five diarylethylamines were evaluated in mono-
amine reuptake inhibition assays. Functional potencies (IC50) of the compounds for reuptake
inhibition at DAT, NET and SERT are given in Table 2. Consistent with the lack of SERT affin-
ity in the binding assays, most of the target compounds failed to show functional activity when
screened at 10 μM. Only 4-MXP displayed weak reuptake inhibition (IC50 = 19.0 μM) at SERT.
Overall there was good agreement between the functional potency (IC50) in the uptake assays
and receptor binding affinities (Ki) for DAT and NET. For example, the most potent reuptake
inhibitor evaluated, 3-MXP, also had the highest affinities at DAT and NET. It is unknown
whether monoamine reuptake inhibition contributes to the pharmacology of diarylethylamines
in vivo. Interestingly, many arylcycloalkylamines also have been reported to have affinity at
DAT, NET and SERT [34, 35]. Dual inhibition of NMDAR and monoamine reuptake may pro-
vide clinically relevant polypharmacology with therapeutic potential in a number of areas,
including neurodegenerative diseases, epilepsy and depression.
Effect on NMDA receptor-mediated field EPSPs. Fig 3 shows the effects of target and
reference compounds on fEPSPs recorded from CA1 neurons in hippocampal slices following
Schaffer collateral stimulation. In Fig 3A and 3B, a cocktail of compounds was used to block
the AMPA and GABA receptor-mediated events and the stimulus strength was increased to
provide a submaximal NMDAR-fEPSP. Fig 3A shows the rapid and near maximal effect of the
competitive NMDAR antagonist, D-AP5 (10 μM). The small persistent deflection, measured as
<20%, is likely to represent a combination of non-glutamatergic synaptic transmission and
stimulus artifact.
Using the same experimental design, DPH 10 μM produced a similar but much slower
reduction of the NMDAR-fEPSP. Equilibrium was not achieved during the 3 h superfusion
(Fig 3B).
Using the same protocol as in Fig 3B, nine compounds were initially tested at 10 μM; all
reduced the NMDAR-fEPSP recorded from CA1 neurones following Schaffer collateral
Table 2. Inhibition potencies of 1,2-diarylethylamines as monoamine transporter reuptake inhibitors.
IC50 (μM)
Compound DAT NET SERT
DPH 1.99 (0.91) 9.25 (0.97) >10 μM
2-MXP 30.0 (0.81) 35.2 (2.04) >10 μM
3-MXP 0.587 (0.92) 2.71 (0.95) >10 μM
4-MXP 2.23 (0.96) 22.5 (1.75) 19.0 (1.12)
2-Cl-DPH 10.5 (0.65) 27.1 (1.02) >10 μM
IC50 values shown in μM. Hill slopes shown in parenthesis. ND–IC50 values were not determined because
compounds showed less than 50% inhibition of uptake at 10 μM during a preliminary screening.
doi:10.1371/journal.pone.0157021.t002
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stimulation. In all cases, the NMDAR-fEPSP declined slowly in the presence of both the DPH
analogues and the established channel blocking NMDAR antagonists (Fig 4). Only for keta-
mine, memantine and 4-MXP was a submaximal plateau level of inhibition achieved. Similarly
at 1 μM for most of the compounds, the slow kinetics did not allow submaximal plateau
responses to be reached in a practical time period which makes estimating potency difficult
(Fig 4). Even 12 h was not long enough to achieve maximal effects, as was found for example
with 1 μMDPH, so exponential plots (see Fig 3D), were used to estimate the half-time and the
Fig 3. Comparison of effect of compounds on hippocampal fEPSPs. A & B. Graphs showing basic
method for studying effect of compounds on NMDAR-fEPSPs in CA1 region comparing effects of 10 μM
D-AP5 (A) and DPH (B). After 30 min baseline recording (a), AMPA and GABA receptor mediated events
were blocked pharmacologically (b), the stimulus strength increased and a new baseline was obtained for the
NMDAR-fEPSP (c) before administering the test compound for 3 h (d). Note firstly the difference in shape
between the AMPA receptor-mediated (a) and the NMDA receptor-mediated (c) fEPSPs, and secondly the
slow onset of the pharmacological block by DPH (B) compared with D-AP5 (A). C. AMPA receptor-mediated
fEPSPs (a) were not reduced by 50/100 μM 2-MXP (b) but the remaining NMDAR-fEPSPs after AMPA and
GABA receptor antagonism were abolished in the presence of 10 μM 2-MXP(c). D. Superimposed single
exponentials, showing time course of reduction of NMDAR-fEPSP by 1 μM test compounds superfused for
up to 12 h.
doi:10.1371/journal.pone.0157021.g003
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minimum plateau values achieved by concentrations of 1 and 10 μM, and 0.3 μM for MK-801
(data not shown). Relative potencies of the compounds were approximated from rates of antag-
onism and the plateau levels reached. Ranking of these relative potencies (MK-801> PCP>
2-Cl-DPHDPH 3-MXP 2-MXP> Ketamine> 4-MXPmemantine) correlated with
relative potencies in binding assays, which gave a Spearman’s rank correlation coefficient of
0.78 (p = 0.0172, two-tailed).
To examine the specificity of DPH analogues, 2-MXP was superfused at 50 (n = 2) and 100 μM
(n = 1) in the absence of AMPA and GABA receptor antagonists (Fig 3C). No reduction of the
AMPA receptor-mediated fEPSP was seen, rather, there was a small increase, which may represent
reduced NMDAR-mediated excitation of inhibitory interneurons. These data suggest that 2-MXP
was>50 times more potent as an antagonist of NMDAR than of AMPA receptor responses.
Unlike D-AP5 and ketamine, no signs of recovery from antagonism with the 1,2-diarylethy-
lamines were seen during 2 h of superfusion in control aCSF (preliminary observations–not
illustrated). Such slow in vitro kinetics are more reminiscent of MK-801 than of ketamine, as
illustrated here (Fig 3D).
Fig 4. Graphs showing the time course of reduction of the NMDAR-fEPSPs by nine compounds. Each
graph shows the average fEPSP amplitude of 3–5 experiments expressed as a percentage of the amplitude
during the prior baseline recording. Drugs were added to the aCSF at concentrations of either 1 μM (blue) or
10 μM (red). The figures on the graphs give i) the time to reach half the maximal response for each drug
concentration and ii) the maximal effect; values derived from single exponential curve-fitting. In the case of
memantine and 4-MXP only the 10 μM concentration was tested.
doi:10.1371/journal.pone.0157021.g004
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In Vivo Pre-pulse Inhibition Experiments
The startle response is attenuated if the startle-inducing stimulus is preceded by a weak sub-
threshold prepulse. This phenomenon, known as prepulse inhibition (PPI), serves as an opera-
tional measure of sensorimotor gating, a type of pre-attentional sensory filtering [45].
NMDAR antagonists with dissociative effects, including PCP, ketamine, methoxetamine, MK-
801, and dextrorphan, produce disruptions of PPI in rats [32, 33, 46]. The dissociative and hal-
lucinogenic effects of NMDAR antagonists are believed to reflect a loss of subcortical filtering
mechanisms, resulting in cortical sensory overload [47]. Hence, the PPI disruption produced
by NMDAR antagonists may reflect the information processing deficits that contribute to their
dissociative effects.
DPH significantly reduced PPI (F(4,45) = 11.33, p<0.0001; Fig 5A1). PPI was assessed
using 3 prepulse intensities (68, 71, and 78-dB above background), but there was no interaction
between treatment and prepulse intensity (F(8,90) = 1.89, NS), so the PPI data were collapsed
across the three prepulse intensities. Administration of 10 mg/kg DPH significantly reduced
average PPI (p<0.01, Tukey's test). There was a significant main effect of prepulse intensity in
this experiment (F(2,90) = 93.17, p<0.0001) and in all subsequent tests (data not shown).
Similar to the first dose-response experiment, DPH significantly reduced PPI at higher
doses (F(5,54) = 31.06, p<0.0001; Fig 5A2). Although here there was an interaction between
treatment and prepulse intensity (F(10,108) = 7.30, p<0.0001), the 10, 20, and 30 mg/kg doses
of DPH reduced PPI at all three prepulse intensities (p<0.01, Tukey’s test). DPH reduced aver-
age PPI with an ED50 = 9.5 mg/kg (95% CI 5.9–15.1 mg/kg), which is equivalent to 31.5 (19.5–
50.0) μmol/kg.
In contrast to the results with DPH, 2-MXP did not alter PPI at doses up to 10 mg/kg (Main
effect: F(4,44) = 1.03, NS; Fig 5B1). When tested at 20 mg/kg, however, 2-MXP did disrupt PPI
(Main effect: F(1,22) = 41.93, p<0.0001). Unfortunately, it was not possible to fully characterize
the dose-response of 2-MXP because of the limited amount of drug available for testing.
Administration of 20 mg/kg 2-MXP significantly reduced the acoustic startle response
(ASR) from 175.9 ± 29.2 to 78.8 ± 11.9 (Main effect: F(1,22) = 9.55, p<0.0053). To confirm
whether the effect of 2-MXP on PPI was independent of changes in the magnitude of the ASR,
we examined the effect on PPI in subgroups of animals matched for startle level.[48] This was
an important control because large reductions in ASR can potentially impair PPI due to floor
effects; therefore, it was important to determine whether drug effects on PPI and ASR were
independent. Eight animals with overlapping startle responses were chosen from each group
(mean ± SEM = 128.5 ± 14.4 and 100.7 ± 10.1). Though 2-MXP had no effect on ASR magni-
tude in those subgroups (F(1,14) = 2.49, NS), PPI was still significantly reduced (Main effect of
2-MXP: F(1,14) = 53.47, p<0.0001). Hence, the PPI disruption produced by 2-MXP was not
caused by changes in ASR magnitude. In contrast to 2-MXP, DPH did not alter the magnitude
of the ASR in either experiment (F(4,45) = 0.95, NS; F(5,54) = 0.82, NS).
An unexpected observation was the fact that DPH and 2-MXP were less potent in the PPI
experiments than might be anticipated based on their high NMDAR affinities. Compared with
DPH, PCP displaced [3H]MK-801 with 3-fold lower affinity, but altered PPI with 10-fold
higher potency (PCP disrupts PPI with an ED50 = 3.15 μmol/kg [49]). Although DPH binds to
the NMDAR with ~18-fold higher affinity than ketamine (Table 1), DPH was substantially less
potent than ketamine enantiomers than DPH in PPI experiments in rats.[49]
Likewise, anecdotal reports in humans [13] suggest DPH and 2-MXP may be less potent
than ketamine. Follow-up research is required to address this discrepancy. The pharmacokinet-
ics of 1,2-diphenylethylamines may play a role in their relatively low potency in rats. It is possi-
ble that 1,2-diphenylethylamines are substrates for P-glycoprotein transporters or are more
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rapidly metabolized than arylcyclohexylamines. In rats, DPH is metabolized by hydroxylation,
dehydrogenation, and N-dealkylation [19]. The possibility that pharmacokinetic factors may
reduce the potency of DPH and 2-MXP has important clinical implications, particularly in
regards to drug-drug interactions.
Conclusion
Five 1,2-diarylethylamines including the ‘legal highs’ DPH and 2-MXP, were found to be rela-
tively selective NMDAR antagonists. Some off-target interactions were observed and several
Fig 5. Effects of (A) DPH and (B) 2-MXP on prepulse inhibition (PPI). (A1) Effect of DPH at doses ranging
from 1.25–10 mg/kg. 50 rats were used (n = 10/group). (A2) Effect of DPH at doses ranging from 2.5–30 mg/kg.
49 rats were used (n = 9-10/group). (B1) Effect of 2-MXP at doses ranging from 1.25–10 mg/kg. 50 Rats were
used (n = 10/group). (B2) Effect of 20 mg/kg 2-MXP. 24 rats were used (n = 12/group). PPI values shown are
averaged across the 3 prepulse intensities (mean ± SEM). *Significant difference compared with vehicle control,
p<0.01 (Tukey's test).
doi:10.1371/journal.pone.0157021.g005
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compounds also showed moderate nM to μM activity as inhibitors of dopamine and norepineph-
rine reuptake with selectivity over serotonin transport. These compounds also inhibited NMDAR-
mediated field EPSPs with a rank-order similar to their measured NMDAR affinities. Notably, the
compounds showed a slow onset of inhibition which may have significance for their subjective
effects in humans. Finally, DPH was found to reduce average PPI with an ED50 = 9.5 mg/kg (95%
CI 5.9–15.1). 2-MXP showed a significant inhibition of PPI at 20 mg/kg but not 10 mg/kg. Thus,
DPH and 2-MXP are less potent in in vivo PPI experiments than other NMDAR antagonists like
PCP and ketamine, a finding that was not anticipated based on their measured NMDAR affinities.
Taken together, the presented results are consistent with the dissociative effects of these com-
pounds anecdotally reported by human users. These results hold significance for potential thera-
peutic use, governmental regulation and harm reduction strategies.
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